Waverly Advisors 13F: Cuts AstraZeneca (AZN) Stake by $22M

Waverly Advisors Scales Back AstraZeneca Holding

Investment manager Waverly Advisors reduced its stake in AstraZeneca PLC (NYSE:AZN) during the period ended May 15, 2026, according to a Form 13F filing with the Securities and Exchange Commission. The firm is known for active adjustments across various equities, and this move represents a significant pruning of its healthcare portfolio. Form 13F filings are backward-looking and only show holdings at the end of a specific quarter, so they do not capture any trades made since May 15.

Trimming the Position

Waverly Advisors sold 118,483 shares of the biopharmaceutical company, which translated to a 49.8% decrease from its prior holding of 237,819 shares. Following the transaction, the firm owned 119,336 shares of the stock. At the reported market valuation, the remaining stake was worth about $22.6 million.

AstraZeneca Stock Context

Shares of AstraZeneca change hands near $189.62, resting above the 50-day moving average of $164.20 and close to the 200-day moving average of $182.92. The company trades within a 52-week price window that stretches from a low of $145.80 up to $212.71. With a trailing price-to-earnings ratio of 25.16 and a forward price-to-earnings ratio of 14.52, the equity prices in future earnings expectations while maintaining a market valuation above $260 billion.

Analysts Set New Price Targets

Wall Street firms continue to update their views on the drug maker, providing fresh context for institutional adjustments. On August 24, 2026, CICC initiated coverage on the stock with an outperform rating and a $198.00 price target. Broader analyst opinion holds a strong buy consensus recommendation, with a mean price target set at $212.17 based on 11 analyst opinions.

Inside AstraZeneca's Pipeline

AstraZeneca PLC is a global biopharmaceutical business headquartered in Cambridge, United Kingdom. The company discovers, develops, and manufactures prescription medicines for oncology, cardiovascular, renal, metabolic, respiratory, and rare diseases. Its extensive drug portfolio includes treatments like Tagrisso, Imfinzi, Lynparza, and Farxiga, serving patients and medical providers across global markets through local offices and distributors.

What's Ahead for AstraZeneca PLC

Investors monitoring institutional activity will look toward upcoming disclosures and corporate milestones for further direction. AstraZeneca is scheduled to release its next financial results on October 30, 2026. Future regulatory filings will show whether Waverly Advisors continues to pare down its exposure or stabilizes its remaining share count.